Clinical Trial

A Study to Assess the Effectiveness and Safety of Canakinumab in Clinical Use in Patients With Schnitzler's Syndrome

Name: A Study to Assess the Effectiveness and Safety of Canakinumab in Clinical Use in Patients With Schnitzler's Syndrome — clinical trial record (NCT07598422)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

The aim of this study is to assess the effectiveness and safety of Ilaris (canakinumab) in clinical use in patients with Schnitzler's syndrome.

Protocol Amendment History 2 changes

critical Recruitment opened 2026-07-02

notable Enrollment increased: 5 -> 10 participants 2026-07-02

Trial Details

NCT Number	NCT07598422
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Schnitzler Syndrome
Enrollment	10 participants
Start Date	2026-05-13
Primary Completion	2032-06-30 (estimated)
Study Completion	2032-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-01